JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Issues journals
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 3
DOI:10.33266/1024-6177-2025-70-2-99-107
W.Yu. Ussov1, S.M. Minin1, Zh.Zh. Anashbayev1, S.I. Sazonova2,
O.I. Belichenko3, E.A. Golovina4, Yu.B. Lishmanov2, A.M. Cherniavsky1
Quantitative Brain SPECT/CT with 99mTc-Technetril
for Visualization and Assessment of the Functional State of Pituitary Adenomas
1 E.N. Meshalkin National Research Medical Center, Novosibirsk, Russia
2 Scientific Research Institute of Cardiology, Tomsk, Russia
3 Russian University of Sports GTSOLIFK, Moscow, Russia
4 National Research Tomsk Polytechnic University, Tomsk, Russia
Contact person: Ussov Wladimir Yuryevich, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. , This email address is being protected from spambots. You need JavaScript enabled to view it.
Summary
Purpose: We tried to adapt the methodology for quantifying the accumulation of 99mTc-technetril (99mTc-MIBI) in pituitary adenomas, present a pharmacokinetic model for calculating blood flow in the pituitary gland based on the accumulation of 99mTc-technetril and evaluate their relationship with the level of prolactin in the blood in some pathological conditions.
Material and methods: The tumor blood flow (TBF) was calculated using the standardized radiopharmaceutical absorption value (SUV) and the minute volume of the heart (MV) as TBF = SUV99mTc-technetril × (MV / BodyWeight) × 100, where 100 is the conversion coefficient for representing the result in generally accepted units of ml/min/100 cm3 of tissue. The value of
SUV99mTc-technetril can be determined using modern digital tomographic gamma cameras automatically, using source calibration with graduated specific radioactivity, or using phantoms with known radioactivity, with the construction of a regression relationship local kBq activity/ml – scintillation count per voxel and determining the true accumulation of radiopharmacutical in the tissue tumors, in kBq/cm3 units of tissue.
SPECT/CT of the brain with 99mTc-technetril (185–240 MBq, Gemini 700 gamma cameras and GE Discovery NM/CT 670 Pro) was performed in 8 patients without pituitary pathology (4 men and women, 34–63 years old) – control group, 9 patients with pituitary microadenomas (5 women and 4 men, 32–51 years old), and 8 patients (5 women and 3 men, 32–56 years old) with pituitary macroadenomas. All patients in groups 2 and 3 had an increase in blood prolactin levels > 35 mg/l, and all of them then received therapy with bromocriptine 2.5 mg/day or higher.
Results: Visually, SPECT/CT showed nodular inclusion in pituitary micro- and macroadenomas. SUV significantly differed between the groups and amounted to 1.23 ± 0.25 (0.85–1.39) in the control group, respectively, with microadenomas 7,20 ± 1,17 (4,5–12,9) (p < 0.02 compared with the control), and with macroadenomas 12.54 ± 3.62 (3.9–4.85) (p < 0.005). The tissue blood flow was, respectively 9,2 ± 2,0 (6,9–14,2): 36,9 ± 7,3 (26,3–72,3) (p < 0.01): and 68.3 ±14.9 (21.0–78.2)(p < 0.002. SUV99mTc-technetril > 5.8 for pituitary nodule was found to be correlated with blood prolactin levels of over 200 mg/l (p = 0.045). A decrease in the SUV99mTc-technetril of the pituitary gland < 3.9 during therapy with bromocriptine 2.5 mg/day was combined with a decrease in blood prolactin levels below 150 mg/l (p = 0.0482).
Conclusion: SPECT/CT of the brain with 99mTc-technetril is an informative additional method of examining patients with pathology of the hypothalamic-pituitary system and allows determining the standardized amount of radiopharmaceutical absorption, as well as pituitary blood flow. It is advisable to use SPECT/CT of the brain with 99mTc-technetril for prospective monitoring of therapy of pituitary pathology, as an adjunct to MRI. A further study of the role of pituitary SPECT/CT with 99mTc-technetril in a wider population of endocrinological patients is needed for inclusion in the standard algorithm and clinical recommendations for patient examination.
Keywords: SPECT/CT, 99mTc-MIBI, pituitary adenomas, dynamic SPECT, dynamic scintigraphy, pituitary blood flow
For citation: Ussov WYu, Minin SM, Anashbayev ZhZh, Sazonova SI, Belichenko OI, Golovina EA, Lishmanov YuB, Cherniavsky AM. Quantitative Brain SPECT/CT with 99mTc-technetril for Visualization and Assessment of the Functional State of Pituitary Adenomas. Medical Radiology and Radiation Safety. 2025;70(3):99–107. (In Russian). DOI:10.33266/1024-6177-2025-70-3-99-107
References
1. Dedov I.I., Yudenich O.N. State and Development Paths of Domestic Endocrinology. Vestnik Rossiyskoy Akademii Meditsinskikh Nauk = Bulletin of the Russian Academy of Medical Sciences. 2006;9;10:38-45 (In Russ.). EDN HVUTAH.
2. Yakovlev S.A., Pozdnyakov A.V., Panfilenko A.F., Karlova N.A., Tyutin L.A., Grantyn’ V.A. Dynamic Contrast MRI in Radiation Diagnostics of Space-Occupying Lesions of the Brain of Midline Localization. Sibirskiy Meditsinskiy Zhurnal = Siberian Medical Journal. 2008;23;1-2:92-96 (In Russ.). EDN KZLDQT.
3. Makeyev S.S., Semenova V.M. Possibilities of Using SPECT with Tumorotropic Radiopharmaceuticals in Differential Diagnostics of Tumors and Non-Tumor Focal Lesions of the Brain. Ukrainskiy Nevrologicheskiy Zhurnal = Ukrainian Neurological Journal. 2007;4; 5:70-74 (In Russ.). EDN RVBWNP.
4. Makeyev S.S., Koval’ S.S., Guk N.A. Use of Radiopharmaceuticals for Single-Photon Emission Computed Tomography of Pituitary Adenomas. Ukrainskiy Neyrokhirurgicheskiy Zhurnal = Ukrainian Neurosurgical Journal. 2014;5;2:20-24 (In Russ.). EDN SEJOJZ.
5. Iglesias P., Cardona J., Díez J.J. The Pituitary in Nuclear Medicine Imaging. Eur J Intern Med. 2019;68;1:6-12. doi: 10.1016/j.ejim.2019.08.008.
6. Watanabe Y., Mawatari A., Aita K., Sato Y., Wada Y., Nakaoka T., Onoe K., Yamano E., Akamatsu G., Ohnishi A., Shimizu K., Sasaki M., Doi H., Senda M. PET Imaging of 11C-Labeled Thiamine tetrahydrofurfuryl Disulfide, Vitamin B1 Derivative: First-in-Human Study. Biochem Biophys Res Commun. 2021;555;1:7-12. doi: 10.1016/j.bbrc.2021.03.119.
7. Naganawa M., Nabulsi N.B., Matuskey D., Henry S., Ropchan J., Lin S.F., Gao H., Pracitto R., Labaree D., Zhang M.R., Suhara T., Nishino I., Sabia H., Ozaki S., Huang Y., Carson R.E. Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699. J Nucl Med. 2022;63;4:609-614. doi: 10.2967/jnumed.121.262430.
8. Slashchuk K.Yu., Rumyantsev P.O., Degtyarev M.V., Serzhenko S.S., Baranova O.D., Trukhin A.A., Sirota Ya.I. Molecular Visualization of Neuroendocrine Tumors with Somatostatin Receptor Scintigraphy (SPECT/CT) with 99mTc-Tectrotide. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2020;65;2:44-49 (In Russ.). doi: 10.12737/1024-6177-2020-65-2-44-49. EDN FKEVLR.
9. Lybik N., Wale D.J., Wong K.K., Liao E., Viglianti B.L. 68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit. Clin Nucl Med. 2021;46;6:505-506. doi: 10.1097/RLU.0000000000003589.
10. Balcerzyk M., Fernandez-Maza L., Mínguez J.J., De-Miguel M. Preclinical [18F]-Tetrafluoroborate-PET/CT Imaging of Pituitary Gland Hyperplasia. Jpn J Clin Oncol. 2018;48;2:200-201. doi: 10.1093/jjco/hyx189.
11. Vukomanovic V.R., Matovic M., Doknic M., Ignjatovic V., Simic Vukomanovic I,. Djukic S., Peulic M., Djukic A. Clinical Usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the Evaluation of Pituitary Adenomas. Nucl Med Commun. 2019;40;1:41-51. doi: 10.1097/MNM.0000000000000931.
12. Kodina G.Ye., Malysheva A.O. Quality Control of Radiopharmaceuticals in Medical Organizations. Razrabotka i Registratsiya Lekarstvennykh Sredstv = Development and Registration of Drugs. 2017;18;1:88-92 (In Russ.). EDN YKPHDZ.
13. Usov V.Yu., Sukhov V.Yu., Babikov V.Yu., Borodin O.Yu., Vorozhtsova I.N., Lishmanov Yu.B., Udut V.V., Krivonogov N.G. Quantitative Determination of Myocardial Tissue Blood Flow by Single-Photon Emission Computed Tomography Based on Absolute Assessment of 99mTc-Technetril Radiopharmaceutical Accumulation. Translyatsionnaya Meditsina = Translational Medicine. 2022;9;1:29-38 (In Russ.). doi: 10.18705/2311-4495-2022-9-1-29-38.
14. Krivonogov N.G., Minin S.M., Krylov A.L., Lishmanov Yu.B. Scintigraphic Determination of Myocardial Blood Flow. Byulleten’ Sibirskoy Meditsiny = Bulletin of Siberian Medicine. 2013;12;3:111-116 (In Russ.).
15. Kostenikov N.A., Pozdnyakov A.V., Dubrovskaya V.F., Mirolyubova O.Yu., Ilyushchenko Yu.R., Stanzhevskiy A.A. Modern Methods of Radiation Diagnostics of Gliomas. Luchevaya Diagnostika i Terapiya = Radiation Diagnostics and Therapy. 2019;10;2:15-23 (In Russ.).
16. Choudhary V., Bano S. Imaging of the Pituitary: Recent Advances. Indian J. Endocrinol Metab. 2011;3;2:216-223.
17. Choudhury P.S., Savio E., Solanki K.K., Alonso O., Gupta A., Gambini J.P., Doval D., Sharma P., Dondi M. 99mTc Glucarate as a Potential Radiopharmaceutical Agent for Assessment of Tumor Viability: from Bench to the Bed Side. World J Nucl Med. 2012;11;2:47-56.
18. Morozova T.A., Zborovskaya I.A. Pituitary Adenomas: Classification, Clinical Manifestations, Approaches to Treatment and Tactics of Patient Management. Lekarstvennyy Vestnik = Medicinal Bulletin. 2006;3;7:18-21 (In Russ.). EDN YSPYQD.
19. Shcherban’ A.Ye., Cherebillo V.Yu., Smirnova A.V. Preoperative Planning of Patients with Pituitary Tumors (Adenomas) Based on Neuroimaging Data. Vestnik Nevrologii, Psikhiatrii i Neyrokhirurgii = Bulletin of Neurology, Psychiatry and Neurosurgery. 2023;53;2:145-160 (In Russ.). doi: 10.33920/med-01-2302-08. EDN YOUZXK.
20. Khoroshavina A.A., Orlova G.A., Ryzhkova D.V. Radioisotope Diagnostics of Endogenous ACTH-Dependent Hypercorticism. Luchevaya Diagnostika i Terapiya = Radiation Diagnostics and Therapy. 2023;4;14:19-27 (In Russ.). doi: 10.22328/2079-5343-2023-14-4-19-27. EDN ABPTOA.
21. Timofeyeva L.A., Aleshina T.N. Radiation Diagnostics of Non-Palpable Thyroid Nodules. Rossiyskiy Elektronnyy Zhurnal Luchevoy Diagnostiki = Russian Electronic Journal of Radiation Diagnostics. 2014;4;S2:27-28 (In Russ.). EDN MHCWNA.
22. Nikolayeva Ye.A., Tarachkova Ye.V., Sheykh Zh.V., Tyurin I.Ye. The Role of PET/CT in Oncogynecology. Meditsinskaya Vizualizatsiya = Medical Visualization. 2023;27;1:145–157 (In Russ.). doi:10.24835/1607-0763-1198
23. Mine A., Derya C., Bekir U., Alper D., Erman Ç. Clinical Significance of Incidental Pituitary Tc-99m MIBI Uptake on Parathyroid SPECT and Factors Affecting Uptake Intensity. Cancer Biother Radiopharm. 2018;33;7:295-299. doi: 10.24835/1607-0763-1198. Epub 2018 Jun 20.
24. Usov V.Yu., Yaroshevskiy S.P., Garganeyeva A.A., Lishchmanov Yu.B., Teplyakov A.T., Belichenko O.I. Possibilities of Dynamic SPECT with 99mTc-Technetrile in Quantitative Assessment of Pharmacological Correction of Myocardial Blood Flow in Patients with Coronary Heart Disease. Terapevt = Terapevt. 2018;14;7:4-15 (In Russ.).
25. Zolotnitskaya V.P., Amosov V.I., Bedrov A.YA., Moiseyev A.A., Litvinov A.P., Perlov R.B. Evaluation of Arterial Blood Flow in the Microcirculatory Bed of the Lower Extremities in Patients with Chronic Ischemia Using SPECT. Regionarnoye Krovoobrashcheniye i Mikrotsirkulyatsiya = Regional Circulation and Microcirculation. 2024;23;1:37–43 (In Russ.). doi: 10.24884/1682-6655-2024-23-1-37-43.
26. Usov V.Yu., Babikov V.Yu., Minin S.M., Sukhov V.Yu., Kostenikov N.A., Luchich M.A., Samoylova Ye.A., Zheravin A.A., Chernyavskiy A.M. Quantitative SPECT of the Brain with 99mTc-Technetrile in Diagnostics, Evaluation of the Effectiveness of Complex Therapy of Low-Differentiated Gliomas and Prognosis of Patients’ Life. Rossiyskiy Neyrokhirurgicheskiy Zhurnal Imeni Professora A.L.Polenova = Russian Neurosurgical Journal Named after Professor A.L.Polenov. 2023;15;S1:26-27 (In Russ.). EDN QGPXKZ.
27. Belyanin M.L., Pod’yablonskiy A.S., Borodin O.Yu., Belousov M.V., Karpov Ye.N., Filimonov V.D., Shimanovskiy N.L., Usov V.Yu. Synthesis and Preclinical Evaluation of the Imaging Capabilities of 99mTc-DTPA-GDOF as a new Domestic Hepatotropic Drug for Scintigraphic and SPECT Studies. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2022;67;6:44–50 (In Russ.). doi: 10.33266/1024-6177-2022-67-6-44-50. EDN BQPVQN.
28. Narkevich B.Ya. Theoretical Bases of Circulation Modelling in Radionuclide Studies of Hemodinamics. Medical Radiology. 1994; 39(5):58-64 (In Russ.).
29. Sapin M.R., Nikityuk D.B. Dmitry Arkadyevich Zhdanov (on the 100th Anniversary of his Birth). Morfologiya = Morphology. 2008;133;4:47–49 (In Russ.).
30. Minin S.M., Nikitin N.A., Shabanov V.V., Losik D.V., Mikheyenko I.L., Pokushalov Ye.A., Romanov A.B. Radionuclide Assessment of Changes in Myocardial Sympathetic Activity in Patients with Atrial Fibrillation and Healthy Volunteers Using a Gamma Camera on CZT Detectors. Rossiyskiy Elektronnyy Zhurnal Luchevoy Diagnostiki = Russian Electronic Journal of Radiation Diagnostics. 2018;8;2:30-39. doi: 10.21569/2222-7415-2018-8-2-30-39 (In Russ.).
31. Znamenskiy I.A., Dolgushin M.B., Yurchenko A.A., Rostovtseva T.M., Karalkina M.A. Diagnosis of Epilepsy: from Origins to Hybrid PET/MRI Method. Klinicheskaya Praktika = Clinical Practice. 2023;14;3:80-94 (In Russ.). doi: 10.17816/clinpract400254. EDN SXMSKF.
32. Masuda A., Yoshinaga K., Naya M., Manabe O., Yamada S., Iwano H., Okada T., Katoh C., Takeishi Y., Tsutsui H., Tamaki N. Accelerated (99m) Tc-sestamibi Clearance Associated with Mitochondrial Dysfunction and Regional Left Ventricular Dysfunction in Reperfused Myocardium in Patients with Acute Coronary Syndrome. EJNMMI Res. 2016;6;1:41-44. doi: 10.1186/s13550-016-0196-5.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.02.2025. Accepted for publication: 25.03.2025.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 3
DOI:10.33266/1024-6177-2025-70-3-108-116
D.V. Arefyeva, V.B. Firsanov, S.V. Yarmiychuk, A.V. Petushok
Application of the Monte-Carlo Method
for Calibration of a Gamma-ray Scintillation Spectrometer
Scientific Research Institute of Industrial and Marine Medicine, St. Petersburg, Russia
Contact person: D.V. Arefyeva, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To develop a method for calibration of a gamma-ray scintillation spectrometer using the Monte Carlo method.
Material and methods: The subject of the study was a gamma-ray spectrometer designed to measure the energy distribution (spectrum) and determine the activity of gamma-emitting radionuclides. Experimental studies were carried out with a set of exemplary measures of special-purpose activity with radionuclides 241Am, 152Eu, 60Co and 137Cs uniformly deposited on an ion exchange resin. Calibration of the spectrometer was carried out using the MCC 3D program (Monte Carlo Calculations 3D), modeling of the hardware spectrum was performed using the MCA program (MultiChannel Analyzer).
Results: The comparison of experimental and simulated spectra was carried out in the following energy intervals: the interval corresponding to the total peak of total absorption (PTA) for gamma energy lines 1173.2 keV and 1332.5 keV for 60Co and PTA for gamma energy line 661.7 keV for 137Cs; intervals corresponding to Compton scattering in the angle range (30–60)°, (60–90)° and (90–180)° (for the 60Co, the average gamma radiation energy of 1252.9 keV was considered); the interval corresponding to multiple scattering with an energy above 100 keV. It was found that the largest deviation of the simulated spectrum from the experimental one is 12 % for the interval corresponding to multiple scattering, which indicates the possibility of spectrum identity. This assumption was verified for each energy interval using the Pearson consensus criterion. A maximum value of χ2 equal to 6.6 was obtained for the energy interval corresponding to Compton scattering in the angle range (60–90)°, which indicates the acceptability of the hypothesis of the identity of the experimental and simulated spectra. Validation of the proposed method showed that the discrepancy between the calculated and passport activity of the sample was no more than 13 %, which indicates the possibility of using the method for calibration of the gamma spectrometer. The dependences of the efficiency of registration in the PTA on the density of the counting sample are calculated using simulated hardware spectra of single activity.
Conclusion: The proposed method makes it possible to calibrate the spectrometer to calculate the specific activity in samples at various densities and energies using spectrometric equipment equipped with inorganic scintillation crystals.
Keywords: gamma-ray spectrometer, Monte Carlo method, calibration, radiation safety
For citation: Arefyeva DV, Firsanov VB, Yarmiychuk SV, Petushok AV. Application of the Monte-Carlo Method for Calibration of a Gamma-ray Scintillation Spectrometer. Medical Radiology and Radiation Safety. 2025;70(3):108–116. (In Russian). DOI:10.33266/1024-6177-2025-70-3-108-116
References
1. Monte Carlo N-Particle Transport Code. URL: https://ru.wikipedia.org/wiki/MCNP.
2. Fluka Particle Transport Code. URL: https://ru.wikipedia.org/wiki/FLUKA.
3. Penelope. A Code System for Monte Carlo Simulation of Electron and Photon Transport URL: http://www.mcnpvised.com/visedtraining/penelope/penelope0.pdf.
4. Lessons and Training Examples on Geant4. URL: https://dev.asifmoda.com/geant4.
5. Cinelli G., Tositti L., Mostacci D., Bare J. Calibration with MCNP of NaI Detector for the Determination of Natural Radioactivity Levels in the Field. Journal of Environmental Radioactivity. 2019;155;156:31-37.
6. Mouhti I., Elanique A., Messous M.Y. Monte Carlo Modelling of a NaI(Tl) Scintillator Detectors Using MCNP Simulation Code. J. Mater. Environ. Sci. 2017;8;12:4560-4565.
7. Bagayev K.A., Kozlovskiy S.S., Novikov I.E. Program for 3D Simulation Modeling of Detection and Registration Systems of Ionizing Radiation Based on a Developed Graphical Interface. ANRI. 2007;4:35-40 (In Russ.).
8. Spectrometers-Radiometers of Gamma, Beta and Alpha Radiation MKGB-01 “RADEK”: Operation Manual. St. Petersburg, Nauchno Tekhnicheskiy Tsentr Radek Publ., 2012. 60 p. (In Russ.).
9. Scintillation Detectors of Ionizing Radiation Based on Sodium Iodide Crystals Activated by Thallium. TU 2651-001-26083472-2015. Usolye-Sibirskoye, Kristall, 2015. 10 p. (In Russ.).
10. Kapitonov M.I. Yadernaya Rezonansnaya Fluorestsentsiya = Nuclear Resonance Fluorescence.Textbook. Moscow, MGU im. M.V.Lomonosova Publ., 2018. 128 p. (In Russ.).
11. Aref’yeva D.V., Firsanov V.B., Kuruch D.D., et al. Calibration of a Gamma-Ray Scintillation Spectrometer Using the Mathematical Modeling Method. Radiatsionnaya Gigiyena = Radiation Hygiene. 2020;13;4:93-100 (In Russ.). doi: 10.21514/1998-426X-2020-13-4-93-100. EDN ZAAYGU..
12. Silant’yev A.N. Spektrometricheskiy Analiz Radioaktivnykh Prob Vneshney Sredy = Spectrometric Analysis of Radioactive Samples of the External Environment. Leningrad, Gidrometeorologicheskoye Izdatel’stvo Publ., 1969. 185 p. (In Russ.).
13. Malysheva T.A. Chislennyye Metody i Komp’yuternoye Modelirovaniye. Laboratornyy Praktikum po Approksimatsii Funktsiy. Tutorial. St. Petersburg, ITMO Publ., 2016. 33 p. (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.02.2025. Accepted for publication: 25.03.2025.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 2
DOI:10.33266/1024-6177-2025-70-2-5-8
S.A. Abdullaev1, 2, N.F. Raeva1, D.V. Fomina1, T.P. Kalinin3,
T.N. Maksimova4, G.D. Zasukhina1, 5
Thymoquinone (a Component of Nigella Sativa) Reduces Toxic Effects of Radiotherapy and Has Anti-Cancer Potential
1 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
2 Institute of Theoretical and Experimental Biophysics, Pushchino, Russia
3 N.I. Pirogov Russian National Research Medical University, Moscow, Russia
4 I.M. Sechenov First Moscow State Medical University, Moscow, Russia
5 N.I. Vavilov Institute of General Genetics, Moscow, Russia
Contact person: S.A. Abdullaev, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
The review analyzes literature data on the biological properties of thymoquinone (TQ), a component of black cumin (Nigella sativa), which is widely used (mainly in the East) for the prevention and treatment of a number of pathologies, including oncology. Numerous data are provided on the radioprotective properties of TQ on experimental animals associated with the effect on oxidative stress induced by radiation, as well as stimulation of the protective systems of the cell and the body. The effect of TQ in combination with radiation in tumor formation is shown. Given the safety of TQ compared to synthetic protectors, the authors recommend TQ for further research for prevention and treatment of radiation exposure.
Keywords: thymoquinone, radioprotector, antioxidant, radiotherapy
For citation: Abdullaev SA, Raeva NF, Fomina DV, Kalinin TP, Maksimova TN, Zasukhina GD. Thymoquinone (a Component of Nigella Sativa) Reduces Toxic Effects of Radiotherapy and Has Anti-Cancer Potential. Medical Radiology and Radiation Safety. 2025;70(2):5–8. (In Russian). DOI:10.33266/1024-6177-2025-70-2-5-8
References
1. Stasiłowicz-Krzemień A., Gościniak A., Formanowicz D., Cielecka-Piontek J. Natural Guardians: Natural Compounds as Radioprotectors in Cancer Therapy. Int J Mol Sci. 2024;25:6937. doi.org/10.3390/ijms25136937
2. Dogru S., Taysi S., Yugel A. Effects of Thymoquinone in the Lungs of Rats Against Radiation-Induced Oxidative Stress. Eur Rev Med Pharmacol Sci. 2024;28;1:191-198. doi: 10.26355/eurrev_202401_ 34904.
3. Guangmei D., Weishan H., Wenya L., Fasheng W., Jibing Ch. Evolution of Radiation-Induced Dermatitis Treatmеnt. Clin Transl Oncol. 2024;26;9:2142-2155. doi: 10.1007/s12094-024-03460-1.
4. Borah P., Baral A., Paul A.K., Ray U., Bharalee R., Upadhyaya H, et al. Traditional Wisdom in Modern Medicine: Unveiling the Anticancer Efficacy of Northeastern Indian spices. Journal of Herbal Medicine. 2024;100896. doi: 10.1016/j.hermed.2024.100896.
5. Shaban A.R. Molecular Modulation of Chemotherapeutic Agents – Choices for Thymoquinone Nano-Structured Lipid Carrier (Tq-Nls) on Human Liver Cancer Cells. World Journal Internal Medicine and Surgery. 2024;1:24-44.
6. Taysi S., Algburi F.Sh., Mohammed Z.R., Ali O.A., Taysi M.E. Thymoquinone: a Review on its Pharmacological Importance, and its Association with Oxidative Stress, Covid-19, and Radiotherapy. Mini Rev Med Chem. 2022;22;14:1847-1875. doi: 10.2174/1389557522666220104151225.
7. Aslani M., Saadat S., Boskabady M. Comprehensive and Updated Review on Anti-Oxidant Effects of Nigella Sativa and its Constituent, Thymoquinone, in Various Disorders. Iran J Basic Med Sci. 2024;27;8:923-951. doi: 10.22038/IJBMS.2024.75985.16453.
8. Sirinyildiz F., Unay S. N-Methyl-d-Aspartate Receptors and Thymoquinone Induce Apoptosis and Alteration in Mitochondria in Colorectal Cancer Cells. Med Oncol. 2024;41;5:123. doi: 10.1007/s12032-024-02348-y.
9. Pandey R., Natarajan P., Reddy U.K., Du W., Sirbu C., Sissoko M., Hankins G.R. Deciphering the Dose-Dependent Effects of Thymoquinone on Transcriptomic Changes and Cellular Proliferation in Glioblastoma. Preprints. 2024. 2024011894. doi: 10.20944/preprints202401.1894.v1.
10. Isaev N., Genrics E., Stelmashook E. Antioxidant Thymoquinone and its Potential in the Treatment of Neurological Diseases. Antioxidants (Basel). 2023;12;2:433. doi: 10.3390/antiox12020433.
11. Засухина Г.Д., Максимова Т.Н. Перспективы применения тимохинона (компонента Nigella sativa) в профилактике и лечении нейропатологии // Успехи современной биологии. 2024. Т.144. №2. С.165-170. [Zasukhina G.D., Maksimova T.N. Prospects for the Use of Thymoquinone (a Component of Nigella Sativa) in the Prevention and Treatment of Neuropathology. Uspekhi Sovremennoy Biologii = Advances in Modern Biology. 2024;144;2:165-170 (In Russ.)].
12. Ferizi R., Ramadan M., Maxhuni Q. Black Seeds (Nigella Sativa) Medical Application and Pharmaceutical Perspectives. J Pharm Bioallied Sci. 2023;15;2:63-67. doi: 10.4103/jpbs.jpbs_364_22.
13. Салеева Д.В., Раева Н.Ф., Абдуллаев С.А., Максимова Т.Н., Засухина Г.Д. Профилактический и терапевтический потенциал тимохинона при ряде патологий человека на основе определения активации клеточных компонентов, осуществляющих защитные функции по активности генов и некодирующих РНК // Госпитальная медицина: наука и практика. 2023. Т.6. №2. С.27-36. [Saleyeva D.V., Rayeva N.F., Abdullayev S.A., Maksimova T.N., Zasukhina G.D. Preventive and Therapeutic Potential of Thymoquinone in a Number of Human Pathologies Based on the Determination of the Activation of Cellular Components that Perform Protective Functions According to the Activity of Genes and Non-Coding RNA. Gospital’naya Meditsina: Nauka i Praktika = Hospital Medicine: Science and Practice. 2023;6;2:27-36 (In Russ.)]. https://doi.org/10.34852/GM3CVKG.2023.75.38.015.
14. Isaev N.K., Chetverikov N.S., Stelmashook E.V., Genrikhs E.E., Khaspekov L.G., Illarioshkin S.N. Thymoquinone as a Potential Neuroprotector in Acute and Chronic Forms of Cerebral Pathology. Biochemistry (Mosc). 2020;85;2:167-176. doi: 10.1134/S0006297920020042.
15. Silachev D.N., Plotnikov E.Y., Zorova L.D., Pevzner I.B., Sumbatyan N.V., Korshunova G.A., Gulyaev M.V., Pirogov Y.A., Skulachev V.P., Zorov D.B. Neuroprotective Effects of Mitochondria-Targeted Plastoquinone and Thymoquinone in a Rat Model of Brain Ischemia/Reperfusion Injury. Molecules. 2015;20;8:14487-503. doi: 10.3390/molecules200814487.
16. Zhang D., Zhang Y., Wang Z., Lei L. Thymoquinone Attenuates Hepatic Lipid Accumulation by Inducing Autophagy Via AMPK/mTOR/ULK1-Dependent Pathway in Nonalcoholic Fatty Liver Disease. Phytother Res. 2023;37;3:781-797. doi: 10.1002/ptr.7662.
17. Abdullaev S., Minkabirova G., Karmanova E., Bruskov V., Gaziev A. Metformin Prolongs Survival Rate in Mice and Causes Increased Excretion of Cell-Free DNA in the Urine of X-Irradiated Rats. Mutat Res Genet Toxicol Environ Mutagen. 2018;831:13-18. doi: 10.1016/j.mrgentox.2018.05.006.
18. Gaziev A., Abdullaev S., Minkabirova G., Kamenskikh K. X-Rays and Metformin Cause Increased Urinary Excretion of Cell-Free Nuclear and Mitochondrial DNA in Aged Rats. J Circ Biomark. 2016;25;5:1849454416670782. doi: 10.1177/1849454416670782.
19. Abdullaev S.A., Glukhov S.I., Gaziev A.I. Radioprotective and Radiomitigative Effects of Melatonin in Tissues with Different Proliferative Activity. Antioxidants (Basel). 2021;10;12:1885. doi: 10.3390/antiox10121885.
20. Abbas Idris Nour M, Abd-AL-Hassan ZI, Ibrahim Hassan DH. Application of Radiosensitizers in Cancer Radiotherapy, Nanomaterials of Heavy Metals, Drugs and Chemicals with Nanostructure. Current Clinical and Medical Education. 2024;2;5:258-266. https://www.visionpublisher.info/index.php/ ccme/article/view/95.
21. Михайлов В.Ф., Засухина Г.Д. Новый подход к стимуляции защитных систем организма малыми дозами радиации // Успехи современной биологии. 2020. Т.140. №3. С. 244-252. [Mikhaylov V.F., Zasukhina G.D. A New Approach to Stimulating the Body’s Defense Systems with Low Doses of Radiation. Uspekhi Sovremennoy Biologii = Advances in Modern Biology. 2020;140;3:244-252 (In Russ.)]. doi: 10.31857/S0042132420030060.
22. Салеева Д.В., Рождественский Л.М., Раева Н.Ф., Воробьева Е.С., Засухина Г.Д. Механизмы противоопухолевого действия малых доз радиации, связанные с активацией защитных систем клетки // Медицинская радиология и радиационная безопасность. 2023. Т. 68. №1. С. 15-18. [Saleyeva D.V., Rozhdestvenskiy L.M., Rayeva N.F., Vorob’yeva Ye.S., Zasukhina G.D. Mechanisms of Antitumor Action of Low Doses of Radiation Associated with Activation of Cellular Defense Systems. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2023;68;1:15-18 (In Russ.)]. doi:10.33266/1024-6177-2023-68-1-15-18.
23. Herrera F.G., Romero P., Coukos G. Lighting up the Tumor Fire with Low-Dose Irradiation. Trends in Immunology. 2022;43;3:173-179. doi 10.1016/j.it.2022.01.006.
24. Михайлов В.Ф., Салеева Д.В., Шуленина Л.В., Раева Н.Ф., Рождественский Л.М., Засухина Г.Д. Связь между динамикой роста перевивной карциномы Льюиса у мышей и изменением активности генов и некодирующих РНК после рентгеновского облучения в малых дозах // Радиационная биология. Радиоэкология. 2022. Т.62. №1. С. 28-41 [Mikhaylov V.F., Saleyeva D.V., Shulenina L.V., Rayeva N.F., Rozhdestvenskiy L.M., Zasukhina G.D. Relationship Between the Growth Dynamics of Transplantable Lewis Carcinoma in Mice and Changes in the Activity of Genes and Non-Coding RNAs After Low-Dose X-Ray Irradiation. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2022; 62;1:28-41 (In Russ.)]. doi:10.31857/S0869803122010088.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was carried out on the topic of the Technology-3 Federal State Budgetary Educational Institution of Science and Technology named after A.I. Burnazyan (state assignment No. 123011300105-3).
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.12.2024. Accepted for publication: 25.01.2025.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 3
DOI:10.33266/1024-6177-2025-70-3-117-120
A.G. Bezverkhov1, E.N. Alekhin2, Yu.S. Pyshkina2, 3,
А.А. Stanjevsky4, А.V. Logvinenko2
On the Legal Regulation of the Specialties Radiology
and Radiotherapy in the Russian Federation
1 S.P. Korolev Samara National Research University, Samara, Russia
2 Tyumen State Medical University, Tyumen, Russia
3 Samara State Medical University, Samara, Russia
4 A.M. Granov Russian Research Center of Radiology and Surgical Technologies, St. Petersburg, Russia
Contact person: Yu.S. Pyshkina, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To study the specifics of legal and regulatory framework governing the specialties of Radiology (nuclear medicine) and Radiotherapy in the Russian Federation with regard to defining their nomenclature and further regulation.
Material and methods: Radiology, commonly referred to as nuclear medicine, originated in the late 19th century after the discovery of radioactivity. It is now extensively utilized in both diagnostic procedures and therapeutic treatments. However, there is significant confusion surrounding the definition of fundamental terms and concepts related to this branch of medicine, necessitating additional clarifications. The authors analyzed literary sources and legislative bases dedicated to issues of terminological and normative uncertainty in the field of nuclear medicine (radiology) in Russia. Discussed are differences in definitions of key terms such as “nuclear medicine,” “radiopharmaceutical preparation,” “radionuclide therapy,” and “radionuclide diagnostics.” Additionally, the problem of a lack of clear standards and rules in the field of nuclear medicine is raised, leading to difficulties in regulating and financing medical services.
Results: Proposed measures for improving the situation include developing unified terminology and standards, introducing the position of chief external radiotherapist, creating professional standards for radiologists and radiotherapists, and involving professional communities in addressing this issue.
Conclusion: The conducted research underscores the importance of resolving existing problems in legal and regulatory frameworks and terminological discrepancies in the fields of radiology and nuclear medicine in Russia. Emphasis is placed on the necessity of unifying terminology and definitions, establishing clear professional standards for specialists, and developing guidelines for conducting radionuclide studies. These measures should contribute to enhancing the quality of medical care, increasing the efficiency of professionals’ work, and ensuring proper funding of medical services through the compulsory health insurance system. The article proposes solving the identified problem by developing and approving terminology in the specialties of Radiology and Radiotherapy and making amendments to regulatory documentation.
Keywords: radiology, nuclear medicine, radiotherapy, radiation therapy, terminology, instrument of legal regulation
For citation: Bezverkhov AG, Alekhin EN, Pyshkina YuS, Stanjevsky АА, Logvinenko АV. On the Legal Regulation of the Specialties Radiology and Radiotherapy in the Russian Federation. Medical Radiology and Radiation Safety. 2025;70(3):117–120. (In Russian). DOI:10.33266/1024-6177-2025-70-3-117-120
References
1. Najam H., Dearborn M.C., Tafti D. Nuclear Medicine Instrumentation. Treasure Island (FL), StatPearls, 2023.
2. Romanovskiy G.B. Legal Regulation of Nuclear Medicine. Elektronnyy Nauchnyy Zhurnal. Nauka. Obshchestvo. Gosudarstvo. = Electronic Scientific Journal. Science. Society. State. 2017;5:1. URL: http://esj.pnzgu.ru. (In Russ.).
3. International Atomic Energy Agency. Sektsiya Yadernoy Meditsiny i Diagnosticheskoy Vizualizatsii = Nuclear Medicine and Diagnostic Imaging Section. URL: https://www.iaea.org/ru/o-nas/sekciya-yadernoy-mediciny-i-diagnosticheskoy-vizualizacii. (In Russ.).
4. Narkevich B.Ya., Ratner T.G., Ryzhov S.A., Moiseyev A.N. Glossariy Terminov, Abbreviatur i Ponyatiy po Meditsinskoy Radiologii i Radiatsionnoy Bezopasnosti = Glossary of Terms, Abbreviations and Concepts in Medical Radiology and Radiation Safety. Moscow, AMFR Publ., 2022. 204 p. (In Russ.).
5. Society of Nuclear Medicine Employees. Radionuklidnaya Diagnostika dlya Prakticheskikh Vrachey = Radionuclide Diagnostics for Practitioners. Manual. Ed. Yu.B.Lishmanov, V.I.Chernov. Tomsk, STT Publ., 2004. 387 p. (In Russ.).
6. Neyroradiokhirurgiya na Gamma-Nozhe. Ed. A.V.Golanov, V.V.Kostyuchenko. Moscow, IP T.A.Alekseyeva Publ., 2018. 960 p. (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.02.2025. Accepted for publication: 25.03.2025.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 2
DOI:10.33266/1024-6177-2025-70-2-9-15
P.A. Malakhov1, M.V. Pustovalova1, A.V. Aleksandrova1, E.G. Kontareva1,
A.V. Smirnova1, Z. Nofal1, A.N. Osipov1, 2, S.V. Leonov1
Repetitive Confined Migration Leads to an Increase in Clonogenic Activity and Chemoresistanse of Human Non-Small Cell Lung Cancer Cells, Regardless of Their Initial Chemo- and Radiosensitivity
1 Moscow Institute of Physics and Technology (National Research University), Dolgoprudny, Russia
2 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: M.V. Pustovalova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Radiation therapy can treat non-small cell lung cancer (NSCLC), but its effectiveness is limited by the development of tumor radioresistance. Studies have shown that radiation can affect tumor aggressiveness, either reducing or increasing the invasiveness of remaining cancer cells, depending on the cell lines and radiation type. However, the effect of tumor cell migration in the confined porous space of tumor tissue on their phenotypic characteristics is not well understood. This study aimed to investigate how migration in confined spaces affects the phenotypic traits of two NSCLC isogenic cell lines with varying levels of radioresistance, invasiveness, and repopulation ability.
Material and methods: The biophysical impact on the A549 cell line and its isogenic radioresistant subline A549IR was carried out by their sequential triple migration in a limited space of membrane pores with a diameter of 8 μm in Boyden chambers, following the concentration gradient of fetal bovine serum. The ability to repopulate cell populations migrated across membranes was characterized using clonogenic analysis. We assessed markers such as Ki67 (cell cycle activity), vimentin (a cytoskeletal protein linked to migration and metastasis), and fluorescent nanosensor uptake (indicating metastasis potential) through quantitative analysis of digital images from high-content imaging of individual cells. A standard method for determining cell mass with the dye sulphorodamine B after exposure to different concentrations of cisplatin was used to assess the chemosensitivity of tumor cells before and after migration.
Results and Conclusion: The study shows that repeated migration through an 8 μm pore, which simulates conditions cancer cells experience during metastasis, deforms the nuclei of non-small cell lung cancer (NSCLC) cells. This deformation reduces Ki67-related chromatin reorganization and alters gene expression, notably increasing vimentin. This results in increased chemoresistance and a greater likelihood of repopulation and metastasis in these cells, regardless of their initial ability to migrate or their sensitivity to chemotherapy and radiation.
Keywords: non-small cell lung cancer, radioresistance, chemoresistance, confined migration, metastatic activity, endocytosis, nanosensors
For citation: Malakhov PA, Pustovalova MV, Aleksandrova AV, Kontareva EG, Smirnova AV, Nofal Z, Osipov AN, Leonov SV. Repetitive Confined Migration Leads to an Increase in Clonogenic Activity and Chemoresistanse of Human Non-Small Cell Lung Cancer Cells, Regardless of Their Initial Chemo- and Radiosensitivity. Medical Radiology and Radiation Safety. 2025;70(2):9–15. (In Russian). DOI:10.33266/1024-6177-2025-70-2-9-15
References
1. Aupérin A., Le Péchoux C., Rolland E., et al. Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. J Clin On col. 2010;28;13:2181-2190. doi: 10.1200/JCO.2009.26.2543. PMID: 20351327.
2. Friedl P., Wolf K. Tumour-Cell Invasion and Migration: Diversity and Escape Mechanisms. Nat Rev Cancer. 2003;3;5:362 374. doi:10.1038/nrc1075. PMID: 12724734.
3. Fanfone D., Wu Z., Mammi J., et al. Confined Migration Promotes Cancer Metastasis Through Resistance to Anoikis and Increased Invasiveness. Elife. 2022;11:e73150. doi:10.7554/ eLife.73150. PMID: 35256052.
4. Fujita, M., Yamada, S., & Imai, T. (2015). Irradiation induces diverse changes in invasive potential in cancer cell lines. Seminars in cancer biology, 35, 45–52. https:// doi.org/10.1016/j.semcancer.2015.09.003
5. Shieh A.C. Biomechanical Forces Shape the Tumor Microenvironment. Ann Biomed Eng. 2011;39;5:1379-1389. doi:10.1007/ s10439-011-0252-2. PMID: 21253819.
6. Pustovalova M., Alhaddad L., Smetanina N., et al. The p53 53BP1-Related Survival of A549 and H1299 Human Lung Cancer Cells after Multifractionated Radiotherapy Demonstrated Different Response to Additional Acute X-ray Exposure. Int J Mol Sci. 2020;21;9:3342. doi:10.3390/ijms21093342. PMID: 32397297.
7. Merkher Y., Kontareva E., Bogdan E., et al. Encapsulation and Adhesion of Nanoparticles as a Potential Biomarker for TNBC Cells Metastatic Propensity. Sci Rep. 2023;13;1:12289. doi:10.1038/s41598-023-33540-1. PMID: 37516753.
8. Wang M., Yi J., Gao H., et al. Radiation-Induced YAP/TEAD4 Binding Confers Non-Small Cell Lung Cancer Radioresistance Via Promoting NRP1 Transcription. Cell Death Dis. 2024;15;8:619. doi:10.1038/s41419-024-07017-6. PMID: 39187525.
9. Alhaddad L., Pustovalova M., Blokhina T., Chuprov-Netochin R., Osipov A.N., Leonov S. IR-Surviving NSCLC Cells Exhibit Different Patterns of Molecular and Cellular Reactions Relating to the Multifraction Irradiation Regimen and p53-Family Proteins Expression. Cancers (Basel). 2021;13;11:2669. doi:10.3390/cancers13112669. PMID: 34071477.
10. Gan, Z., Ding, L., Burckhardt, C. J., Lowery, J., Zaritsky, A., Sitterley, K., Mota, A., Costigliola, N., Starker, C.G., Voytas, D.F., Tytell, J., Goldman, R.D., & Danuser, G. (2016). Vimentin Intermediate Filaments Template Microtubule Networks to Enhance Persistence in Cell Polarity and Directed Migration. Cell systems, 3(3), 252–263.e8.
11. Mendez, M. G., Restle, D., & Janmey, P. A. (2014). Vimentin enhances cell elastic behavior and protects against compressive stress. Biophysical journal, 107(2), 314–323. https://doi. org/10.1016/j.bpj.2014.04.050/
12. Hu, J., Li, Y., Hao, Y., Zheng, T., Gupta, S. K., Parada, G. A., Wu, H., Lin, S., Wang, S., Zhao, X., Goldman, R. D., Cai, S., & Guo, M. (2019). High stretchability, strength, and toughness of living cells enabled by hyperelastic vimentin intermediate filaments. Proceedings of the National Academy of Sciences of the United States of America, 116(35), 17175–17180. https:// doi.org/10.1073/pnas.1903890116.
13. Xuan, B., Ghosh, D., Cheney, E. M., Clifton, E. M., & Dawson, M. R. (2018). Dysregulation in Actin Cytoskeletal Organization Drives Increased Stiffness and Migratory Persistence in Polyploidal Giant Cancer Cells. Scientific reports, 8(1), 11935. https://doi.org/10.1038/s41598-018-29817-5.
14. Esue O., Carson A.A., Tseng Y., Wirtz D. A Direct Interaction between Actin and Vimentin Filaments Mediated by the Tail Domain of Vimentin. J Biol Chem. 2006;281;41:30393-30399. doi:10.1074/jbc.M605452200. PMID: 16901892.
15. Shen Q, Hill T, Cai X, Bui L, Barakat R, Hills E, Almugaiteeb T, Babu A, Mckernan PH, Zalles M, Battiste JD, Kim YT. Physical confinement during cancer stem cell-like behavior. Cancer Lett. 2021 May 28;506:142-151. doi: 10.1016/j.canlet.2021.01.020
16. Bunn P.A. Jr. The Expanding Role of Cisplatin in the Treatment of Non-Small-Cell Lung Cancer. Semin Oncol. 1989;16;4;6:10 21. PMID: 2548280.
17. Cho K., Choi E.S., Kim J.H., Son J.W., Kim E. Numerical Learning of Deep Features from Drug-Exposed Cell Images to Calculate IC50 without Staining. Sci Rep. 2022;12;1:6610. Published 2022 Apr 22. doi:10.1038/s41598-022-10643-9. PMID: 35459284.
18. Xuan, B., Ghosh, D., Jiang, J., Shao, R., & Dawson, 19. M.R. (2020). Vimentin filaments drive migratory persistence in polyploidal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 117(43), 26756–26765. https://doi. org/10.1073/pnas.2011912117
19. Valeriote, F. and L. van Putten, Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer research, 1975. 35(10): p. 2619-2630;
20. Stover, D.G., et al, The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis. Clinical Cancer Research, 2016. 22(24): p. 6039-6050.
21. Tubiana, M. et al, The long-term prognostic significance of the thymidine labelling index in breast cancer. International journal of cancer, 1984. 33(4): p. 441−445
22. Miller, I. et al, Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell reports, 2018. 24(5): p. 1105−1112. e5
23. Sobecki, M., et al, The cell proliferation antigen Ki-67 organises heterochromatin. elife, 2016. 5: p. e13722;
24. Mrouj, K., et al, Ki 67 regulates global gene expression and promotes sequential stages of carcinogenesis. Proceedings of the National Academy of Sciences, 2021. 118(10): p. e2026507118.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was supported by the Ministry of Science and Higher Education of the Russian Federation (State Assignment): “Development of local drug delivery systems for medical purposes”, number FSMG-2023-0015, agreement number No. 075-03-2024-117 dated 17.01.2024.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.12.2024. Accepted for publication: 25.01.2025.